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Psoriasis is a chronic inflammatory skin disease affecting 2–3% of worldwide population.
The extent of skin involvement is variable, ranging from a few localized plaques to general-
ized involvement. Moderate to severe psoriasis (>10% of body surface area) is frequently
associated with psoriatic arthritis and metabolic diseases, like abdominal obesity, diabetes,
non-alcoholic fatty liver disease, dyslipidemia, metabolic syndrome, and chronic kidney dis-
ease. A common genetic background as well as several acquired risk factors links psoriasis
to comorbidities. From a clinical prespective, the understanding of the patients in the con-
text of these comorbidities is very important to ensure that treatment is tailored to meet
the individual patient needs. Indeed, some pharmacological treatments may negatively
affect cardio-metabolic comorbidities, and have important interactions with drugs that are
commonly used to treat them. Non-pharmacological intervention such as diet, smoking ces-
sation, and physical exercise could both improve the response to treatments for psoriasis
and reduce the cardiovascular risk.
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INTRODUCTION
Psoriasis is an immune-mediated chronic inflammatory disease
affecting approximately 2–3% of Caucasian population (1). It can
occur at any age, although the majority of cases develop before
the age of 40 years and it is uncommon in children. Psoriasis is
a complex disease with a strong genetic background (1). So far,
about 20 chromosome regions have been proposed to harbor pso-
riasis susceptibility genes, which affect mostly innate and adaptive
immune responses. The locus carrying the highest risk is the class I
region of the major histocompatibility antigen cluster, which har-
bor the human leukocyte antigen Cw6 and is associated to early
onset psoriasis (2). The current understanding of the molecular
pathogenesis of psoriasis assigns central importance to the inter-
action between acquired and innate immunity (3). Chronic plaque
psoriasis is the most common type of the disease (4). The extent of
skin involvement is widely variable, ranging from a few localized
plaques at extensor sites to generalized involvement. Moderate to
severe psoriasis is defined if the body surface involvement is>10%.
Patients with psoriasis, like those with other major medical disor-
ders, have a worse quality of life, reduced life expectancy as well as
employment and income (5).
CHRONIC PLAQUE PSORIASIS AND METABOLIC
COMORBIDITIES
Several epidemiological studies have confirmed that moderate to
severe psoriasis is strongly associated with cardio-metabolic disor-
ders including hypertension, obesity, type 2 diabetes, dyslipidemia,
non-alcoholic fatty liver disease (NAFLD), metabolic syndrome,
and chronic kidney disease (CKD) (6). In particular, patients with
psoriasis are more frequently overweight or obese than the general
population, and the severity of psoriasis is correlated to body mass
index (BMI) (7, 8). The association between obesity and psori-
asis has been recently confirmed also in pediatric patients (9).
Obesity generally precedes the development of psoriasis and the
BMI is correlated to an increased risk of incident psoriasis. Several
measures of adiposity, including BMI, waist, and hip circumfer-
ence and waist–hip ratio have been reported as independent risk
factors for the development of psoriasis and psoriatic arthritis
(PsA) (10). The relationships between psoriasis and obesity may
be largely explained by the complex properties of the adipose tis-
sue. Indeed, the adipose tissue is not only a storage fat organ but an
active endocrine organ with many secretory products, such as free
fatty acids, adipocyte-derived hormones, and pro-inflammatory
adipokines, including chemerin, resistin, visfatin, interleukin (IL)-
6, and tumor necrosis factor (TNF)-α (11). In addition, a recent
meta-analysis reported that psoriasis is a risk factor for both
prevalent and incident type 2 diabetes mellitus (12, 13).
Visceral obesity and type 2 diabetes are two main compo-
nents of the metabolic syndrome. The metabolic syndrome is a
set of metabolic disorders, in particular insulin resistance, which
may confer a higher pro-inflammatory and pro-thrombotic risk.
The diagnosis of metabolic syndrome is confirmed in presence
of three or more of the following conditions including abdom-
inal obesity (waist circumference >102 cm in men; >88 cm in
women), elevated serum triglycerides [>150 mg/dl (1.7 mmol/l)
or treatment], low HDL cholesterol [men <40 mg/dl (1 mmol/l);
women <50 mg/dl (1.3 mmol/l); or treatment], elevated blood
pressure (>130/85 mmHg or treatment), and elevated fasting glu-
cose (>100 mg/dL or treatment) (14). In a cross-sectional study,
we found that patients with psoriasis had a higher prevalence
of metabolic syndrome than those with other inflammatory skin
diseases after controlling for sex and age (30.1 vs. 20.6%, OR: 1.65,
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95% CI 1.16–2.35) (14). The association between psoriasis and
metabolic syndrome has been also recently confirmed in a meta-
analysis showing that psoriasis carries a pooled odds ratio for
metabolic syndrome of 2.26 (95% CI 1.70–3.01) (15). NAFLD
is a spectrum of progressive liver disease that encompasses sim-
ple steatosis, non-alcoholic steato-hepatitis (NASH), fibrosis, and
ultimately cirrhosis. NAFLD is recognized as the hepatic expres-
sion of the metabolic syndrome, as these conditions have insulin
resistance as a common pathophysiological mechanism (16). We
found that the prevalence of NAFLD in patients with chronic
plaque psoriasis was remarkably greater than that in non-psoriasis
controls (47 vs. 28%; p< 0.0001) who were matched by age, sex,
and BMI (17). In a recent Dutch study, NAFLD was diagnosed in
46.2% of patients with psoriasis compared with 33.3% of the con-
trols (p= 0.005) (18). Psoriasis was found associated to NAFLD
independently of alcohol consumption, smoking status, presence
of metabolic syndrome, and serum levels of alanine aminotrans-
ferase (adjusted odds ratio 1.7, 95% CI 1.1–2.6) (18). NAFLD is an
emerging risk factor for cardiovascular diseases (CVD) (19). There
is conflicting evidence as to whether psoriasis is associated with
increased cardiovascular outcomes. Patients with psoriasis show a
higher prevalence of other important CVD risk factors, including
smoking, sedentary habit and dyslipidemia, making them more
susceptible to development of CVD morbidity and mortality, and
particularly young patients with the more severe skin disease (20,
21). Some studies reported that patients with severe psoriasis, but
not those with mild disease, are at increased risk of developing
acute myocardial infarction and stroke, as well as CVD mortal-
ity (22). Uncertainty still remains about whether the increased
CVD risk observed in psoriatic patients is directly attributable
to psoriasis itself or to the effects of multiple co-existing risk
factors (23).
Recently, the association between psoriasis and CKD has also
been reported (24). A retrospective cohort study showed in that
moderate to severe psoriasis is associated with CKD independently
of traditional risk factors. In particular, it was found that 5% of
patients with psoriasis had CKD compared to 2% of controls.
No association was shown in patients with mild disease (with a
body surface area <2%). The relative risk of CKD was observed
being especially increased in younger patients. Nerveless, despite
the attenuation of the association with increasing age, the clini-
cal relevance of the absolute risk of CKD attributable to psoriasis
was demonstrated increasing with age. Because of these findings
closer monitoring for renal insufficiency, such as routine screening
for microalbuminuria and serum creatinine should be performed
in patients with moderate to severe disease. Additionally, the risk
vs. benefit of potentially nephrotoxic drugs such as cyclosporine
in patients with moderate to severe psoriasis should be carefully
considered.
The association between psoriasis and comorbidities could be
explained considering a common genetic background, the sys-
temic effects of chronic inflammation, insulin resistance, and an
unhealthy life-style such as heavy smoking/drinking, over-eating
habit, and sedentary life, which are common in patients with
psoriasis. A meta-analysis of 4 different studies reported that 10
metabolic gene single nucleotide polymorphisms including those
related to CARD14 are closely correlated to both psoriasis and
metabolic disorders, such as diabetes, dyslipidemia, and hyper-
tension (25). Psoriasis and obesity-related inflammatory status
can fuel reciprocally. Indeed, it is likely that cytokines released
from either psoriatic keratinocytes or inflammatory cells infiltrat-
ing psoriatic skin might induce systemic insulin resistance, thus
favoring the development of type 2 diabetes mellitus (11). On
the other hand, it is also possible that the co-existing metabolic
comorbidities might directly contribute to exacerbate psoriatic
inflammation through the release of several pro-inflammatory
mediators from the liver and/or visceral adipose tissues, such as
increased reactive oxygen species, C reactive protein (CRP), IL-6,
and other adipokines (26).
MANAGEMENT OF PATIENTS WITH MODERATE TO SEVERE
PSORIASIS AND METABOLIC COMORBIDITIES
The association between psoriasis and cardio-metabolic disor-
ders has important clinical consequences. Firstly, systemic treat-
ments for psoriasis could negatively affect metabolic comor-
bidities, especially in case of continuous and prolonged use
(Table 1). In particular, methotrexate should be prescribed with
caution in the presence of obesity, diabetes, NAFLD, and heavy
alcohol intake because of the increased risk of liver fibrosis
(27). Transient elastography and FibroTest are effective non-
invasive tools for monitoring hepatotoxicity in patients receiving
methotrexate for psoriasis (28). Moreover, it should be con-
sidered that CKD of older patients could reduce renal clear-
ance of methotrexate favoring toxicity (29). Cyclosporine can
induce or worsen arterial hypertension, increase insulin resis-
tance, and interfere with fatty acid metabolism inducing dys-
lipidemia and hyperuricemia (30). Then, the drug interaction
between cyclosporine and statins, which are commonly used
for hypercholesterolemia, could potentially induce rabdomiolysis
(31). Consequently, cyclosporine should be used with caution in
psoriatic patients with features of the metabolic syndrome. More-
over, the presence of an established CKD is a contraindication for
cyclosporine use. Acitretin could also favor hypertriglyceridemia
and/or hypercholesterolemia, although severe cases are rare (30).
PUVA and narrowband UVB therapy are not expected to cause sig-
nificant changes in metabolic parameters (32), but are impractical
for many patients.
Generally, biological therapies do not negatively affect meta-
bolic parameters as conventional treatments can do. However,
Table 1 | Systemic treatments for psoriasis could negatively affect the
components of metabolic syndrome.
MTX CsA Acitretin Anti-TNF-α Ustekinumab
Hyperlipidemia No Yes Yes No No
Hypertension No Yes No No No
Obesity No No No Yes No
Diabetes No Yes No No No
NAFLD Yes No No No No
Decreased renal
function
Yes Yes No No No
NAFLD, non-alcoholic fatty liver disease.
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clinically significant dyslipidemia has been occasionally reported
in patients receiving TNF-α antagonists, but this is not a common
issue in clinical practice (33). A body weight gain could occur in
patients treated with TNF-α antagonists (34, 35). Weight changes
are induced mainly by fat mass gain in patients with psoriasis
receiving TNF-α antagonists (34). By contrast, ustekinumab is not
associated to body weight increase in patients with chronic plaque
psoriasis (36).The effects of anti-TNF therapy on insulin sensitiv-
ity is controversial (37, 38). The effects of TNF-α inhibitors on
glycemic parameters and insulin resistance in patients with pso-
riasis have been addressed mostly in small studies by means of
the Homeostasis Model Assessment (HOMA) and the Quantita-
tive Insulin Sensitivity Check Index (QUICKI), two widely used
non-invasive surrogate markers of insulin resistance and sensitiv-
ity, respectively. A randomized, double-blind study in 12 psoriatic
patients at high risk of developing type 2 diabetes mellitus failed
to see a significant effect of a 2-week treatment with etanercept on
insulin secretion and sensitivity (39). In contrast, a 24-week study
in nine patients with stable active plaque psoriasis treated with
etanercept found a significant reduction in insulin plasma levels,
with a significant improvement in insulin resistance as suggested
by the decrease in the HOMA index (40). No significant changes in
insulin sensitivity or in the levels of fasting blood glucose were seen
in a study in 18 patients with psoriasis after 12 weeks of treatment
with adalimumab (41). Solomon et al. found that patients with
rheumatoid arthritis or psoriasis receiving TNF-inhibitors had
lower risk of developing diabetes mellitus compared with other
treatments (42).
Biologics targeting the IL-12/23 pathway have proven to be
highly effective in psoriasis, but their safety on CDV risk is still a
matter of controversy. Indeed, briakinumab was withdrawn from
clinical development because of an imbalance of major CDV
events in the treatment group compared to controls (43). Con-
sequently, there have been similar concerns over the safety of
ustekinumab, although data from international post-marketing
registry does not show any risk (44). To date, the Food and Drug
Administration has not issued changes to the prescribing infor-
mation for ustekinumab related to CDV risk. It could be also
considered that drugs used mainly in the treatment of arter-
ial hypertension including beta-blockers and ACE-inhibitors may
worsen psoriasis in some patients (45). Finally, patients with mod-
erate to severe psoriasis are candidate to interventions aimed to
reduce their CDV risk including hypo-caloric diet, regular phys-
ical activity, and smoking cessation. Low calorie diet inducing a
moderate weight loss (i.e., 5–10% of body weight) increases the
responsiveness of obese patients to any systemic treatments (46–
48). Smoking habit has been associated to onset and worsening
of psoriasis, and smoking cessation can positively affect the dis-
ease course (49). Patients with psoriasis exhibit decreased levels of
physical activity, possibly for both psychological and physiologi-
cal reasons (50). Regular physical activity may lower the risk of
incident psoriasis and have also a beneficial effect on the natural
course of the disease influencing the severity as well as metabolic
comorbidities (51).
From a clinical prospective, the understanding of the patients
in the context of these comorbidities is very important to ensure
that treatment is tailored to meet the individual patient needs.
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